C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 213/74 (2006.01) A61K 31/44 (2006.01) A61P 19/00 (2006.01) A61P 35/00 (2006.01) C07D 213/61 (2006.01) C07D 213/73 (2006.01) C07D 213/75 (2006.01) C07D 401/04 (2006.01) C07D 401/12 (2006.01) C07D 401/14 (2006.01) C07D 409/12 (2006.01) C07D 413/04 (2006.01) C07D 413/14 (2006.01) C07D 417/04 (2006.01) C07D 417/10 (2006.01)
Patent
CA 2493026
VEGFR-2 and VEGFR-3 inhibitory anthranylamidopyridinamides, the production and use thereof as medicaments for the treatment of diseases caused by persistent angiogenesis and intermediates for production of the compounds are disclosed. Said compounds can be used, for example, in tumour or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as for example, stent-induced restenoses, endometriosis, Crohn's disease, Hodgkin's disease, leukaemia, arthritis, such as rheumatoid arthritis, haemangioma, angiofibroma, eye disease, such as diabetic retinopathy, neovascular glaucoma, renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejection and glomerulopathy, fibrotic diseases, such as liver cirrhosis, mesangial cell proliferative diseases, artherosclerosis, injuries to nervous tissue and inhibition of the reocclusion of vessels after balloon catheter treatment, in vessel prosthetics, or after the application of mechanical devices to hold open vessels, such as for example, stents, as immune suppressants, as a support for scar-free wound healing, age spots and contact dermatitis. Said compounds may also be used as VEGFR-3 inhibitors in lymphangiogenesis.
L'invention concerne des anthranylamidopyridinamides inhibant VEGFR-2 et VEGFR-3, leur fabrication et leur utilisation en tant que médicament destiné au traitement de maladies déclenchées par une angiogenèse persistante, ainsi que des produits intermédiaires destinés à la fabrication de ces composés. Les composés selon l'invention peuvent servir d'immunosuppresseurs en cas de croissance de tumeurs et métastases, psoriasis, sarcome de Kaposi, resténose telle que resténose provoquée par stent, endométriose, maladie de Crohn, maladie de Hodgkin, leucémie, arthrite telle qu'arthrite rhumatoïde, hémangiome, angiofibrome, maladies des yeux telles que rétinopathie diabétique, glaucome néovasculaire, maladies des reins telles que glomérulonéphrite, néphropathie diabétique, néphrosclérose maligne, syndrome microangiopathique thrombique, rejets de greffe et glomérulopathie, maladies fibrotiques telles que cirrhose du foie, maladies membrano-prolifératives, artériosclérose, blessures des tissus nerveux et inhibition de la réocclusion de vaisseaux après traitement avec sonde à ballonnet, installation de prothèses vasculaires ou de dispositifs mécaniques servant à maintenir des vaisseaux ouverts tels que des stents, taches de vieillesse ou dermite de contact, ou servir à favoriser une cicatrisation sans traces. Les composés selon l'invention peuvent également servir d'inhibiteurs de VEGFR-3 en cas de lymphangiogenèse.
Haberey Martin
Hess-Stump Holger
Huth Andreas
Ince Stuart
Krueger Martin
Bayer Schering Pharma Aktiengesellschaft
Marks & Clerk
Schering Aktiengesellschaft
LandOfFree
Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridines will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2007727